吲达帕胺

  • 网络Indapamide
吲达帕胺吲达帕胺
  1. 吲达帕胺冻干口腔崩解片在Beagle犬体内药物动力学研究

    Pharmacokinetics of Indapamide Lyophilized Oral Disintegrating Tablets in Beagle Dogs

  2. 目的测定月桂酰吲达帕胺的电离常数(pKa)及分配系数。

    Objective To determine the ionization constant and partition coefficient of lauroyl indapamide .

  3. 目的观察新型噻嗪类利尿剂吲达帕胺逆转左心室肥厚(LVH)的效果。

    Objective To investigate the curative effect of left ventricular hypertrophy ( LVH ) with uretic indapamide .

  4. 前12h平均累计释放度与时间呈良好线性关系,3批样品与进口吲达帕胺缓释片释放曲线基本一致。结论:本品处方合理,制备工艺简单,体外缓释效果明显。

    Conclusion : The formulation with significant sustained-release effect in vitro is rational and the preparation method is simple .

  5. 结论:缬沙坦与吲达帕胺联合应用可显著降低EH患者动态血压水平和血压负荷,改善血压昼夜节律,显著改善胰岛素敏感性。

    Conclusion : Valsartan in combination with indapamide could significantly reduce blood pressure , modulate non-dipper circadian variation and improve insulin sensitivity in patients with EH .

  6. 对非洛地平组、吲达帕胺组分别在治疗3个月、1a后复查血压和心脏血管超声的上述指标。

    For groups A and B all above indices and blood pressure were measured again after 3 month , 1 year of treatment respectively .

  7. 观察自发性高血压大鼠(SHR)服用降压药吲达帕胺后,在血压下降的同时,体内前列腺素系统的变化,并与对照组及正常大鼠比较。

    The influence of indapamide on the prostaglandin system was studied in spontaneously hypertensive rats ( SHR ) and compared with SHR control and normal WKY rats .

  8. 吲达帕胺对自发性高血压大鼠组织6-酮-PGF(1α)、PGE2、PGF(2α)合成及对血浆TXB2的影响

    The Influence of Indapamide on 6-keto-PGF_ ( 1 α), PGE_2 , and PGF_ ( 2 α) Synthesis and Plasma TXB_2 Levels in Spontaneously Hypertensive Rats

  9. 服吲达帕胺组或卡托普利组8周后血压,T3和T4水平较服药前均显著降低(P<005)。

    After 8 weeks treatment , the T 3 and T 4 were decreased in both groups ( all P < 0 05 ) along with blood pressure lowering .

  10. NESTOR研究:缓释型吲达帕胺和依那普利减少高血压合并2型糖尿病患者微蛋白尿的疗效相同

    Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes : The NESTOR study

  11. 目的探讨氯沙坦和吲达帕胺对老年高血压患者的血压、血尿酸及血与尿β2微球蛋白(β2MG)的影响。

    Objective To investigate the effects of losartan and indapamide on blood pressure , uric acid and β 2 microglobulin (β 2 MG ) in senile hypertensive patients .

  12. 方法按自身对照随机交叉双周期试验设计,20名健康志愿者单剂口服进口与国产吲达帕胺缓释片1.5mg,用高效液相色谱-电化学检测法测定血浆中药物浓度。

    Methods A single oral dose and multi - doses of indapamide sustained release tablet were given to 20 healthy male Chinese volunteers .

  13. 结论依那普利和吲达帕胺均有逆转LVH作用,两者联合应用在逆转LVH方面优于单独使用吲达帕胺。

    Conclusion Both enalapril and indapamide can reverse LVH in hypertension patients . It is the best efficacy that enalapril in combination with indapamide to treat essential hypertension accompanied by LVH than those of indapamide single using .

  14. 为寻求合理有效的给药时间,对40例高血压患者进行观察,随机将其分为两组:A组6:00给药,B组8:00给药,均为长效降压药吲达帕胺2.5mg,口服。

    To explore the rational and effective time of administration , 40 observed patients with hypertention were randomly divided into 2 groups . Groups A and B were given 2.5 mg of indapamide , a long acting antihypertensive at 6:00 and 8:00 respectively .

  15. 其中,E厂吲达帕胺片在60min时的累积溶出率小于65%,不符合中国药典规定,其他4厂吲达帕胺片的溶出度均符合规定。

    The cumulative dissolution rate of the Indapamide tablets from manufacturer E was below 65 % at 60 min , which failed to be in line with the specification of China Pharmacopeia , whereas those from the other 4 manufacturers were up to the level specified in China Pharmacopeia .

  16. 方法:以HPMC为骨架材料,以微晶纤维素、乳糖和可压性淀粉调节释放度,对吲达帕胺缓释片的影响因素进行了考察,并采用正交试验设计筛选处方。

    METHODS The effects on the release of indapamide sustained release tablets were observed , and the formulations were screened by the use of HPMC as the gel matrix and MCC , Lactose and Starch to modify the release and by the method of Orthogonal Test .

  17. 目的:研制吲达帕胺胶囊并对其溶出度进行考察。

    Objective : To prepare indapamide capsules and evaluate its dissolution .

  18. 结论月桂酰吲达帕胺为弱酸性亲脂性药物。

    Conclusions Lauroyl indapamide is a weak acid with lipophilic property .

  19. 月桂酰吲达帕胺的电离常数及分配系数的测定

    Determination of the ionization constant and partition coefficient of lauroyl indapamide

  20. 吲达帕胺胶囊的研制与质量控制

    Study on the Preparation and Quality Control of Indapamide Capsules

  21. 吲达帕胺片在2种介质中的溶出度考察

    Study on the Dissolution of Indapamide Tablets in Two Kinds of Medium

  22. 吲达帕胺缓释片的研制及释药机理考察

    Development of indapamide sustained release tablets and study on its release mechanism

  23. 吲达帕胺对高血压病患者降压作用的临床研究

    Clinical Study on Antihypertensive Effect of Indapamide on the Patients with Essential Hypertension

  24. 目的探讨吲达帕胺致低钾血症的易患性。

    Objective To investigate the liability of indapamide-induced kaliopenia .

  25. 吲达帕胺大鼠在体胃、小肠的吸收动力学研究

    Studies on the absorption kinetics of indapamide in rats 's stomachs and intestines

  26. 吲达帕胺治疗高血压病的研究

    A study on treatment of essential hypertension with indapamide

  27. 口服吲达帕胺片人体药动学研究

    Pharmacokinetics of Indapamide by Oral in Human Body

  28. 高效液相色谱流动相手性添加剂法拆分吲达帕胺对映体

    Resolution of Enantiomers of Indapamide by HPLC with Mobile Phase Added with Chiral Agent

  29. 吲达帕胺胶囊人体药动学和生物等效性研究

    Evaluation of pharmacokinetics and bioequivalence of indapamide capsules

  30. 结论吲达帕胺改善心脏功能与结构的效果优于氢氯噻嗪。

    ConclusionThe effect of Indapamide on cardiac function and structure is better than Hydrochlorothiazide .